GT Biopharma Inc. (GTBP) Announces Dr. Jeffrey Miller, Renowned NK Cell Cancer Specialist, Will Present at Cell Therapy Symposia
GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP.PA) announced today that Dr. Jeffrey Miller, Deputy Director of the Masonic Cancer Center, University of Minnesota will be presenting at the Keystone Symposia: Emerging Cellular Therapies: T Cells and Beyond; ‘Novel Ways to Activate and Target NK Cells to Treat Cancer‘. This presentation will highlight GT Biopharma’s TriKE and TetraKE platforms.
Does GT Biopharma (GTBP) have what it takes to be a billion dollar opportunity?
GTBP has been a company we’ve followed along closely and Friday afternoon we saw a surge of trading momentum kick into high gear. In fact by the closing bell, GTBP had rallied by more than 15% and we feel that this momentum could just be gtting started!
An affiliate of BiotechStocks.com (MAPH ENTERPRISES LLC) has been compensated $150,000.00 by a GT Biopharma Inc. for a period beginning Jan 1, 2018 and ending Feb. 1, 2018 now extended till March 1, 2018 for an additional $250,000 paid for by GT Biopharma Inc. to publicly disseminate information about (GTBP). We own zero shares.